CAAs remodel the BC ECM, increase aromatase expression in BC, cause various BC metabolic changes, and induce an immunosuppressive TME, which ultimately promote tumorigenesis, progression, and treatment resistance in BC. Here, CYP19A1 is linked to breast cancer.